dyslipidemia
Conditions
Interventions
SEE-THRU Lipid is a 8-week, prospective, randomized, open, blinded-endpoint (PROBE) study. After a screening phase for eligibility, baseline data are obtained. Then, patients are assigned to receive r
Sponsors
Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with dyslipidema who have not been treated with antidyslipidemic drug.
Exclusion criteria
Exclusion criteria: Exclusion criteria are: history of coronary heart disease, heart failure, or stroke; diabetes mellitus; metabolic syndrome; malignant neoplasm; active inflammatory disease; disorder that requires treatment with statin; pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the change in the plasma S1P concentration and endothelial function from baseline to week 8. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) The change in lipid profiles (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) from baseline to week 8. (2) The change in fasting plasma glucose, C-reactive protein, serotonin, malondialdehyde-modified low-density lipoproteitn (MDA-LDL) from baseline to week 8. (3) The change in urine albumin excretion from baseline to week 8. (4) The change in brachial-ankle pulse wave velocity from baseline to week 8. (5) The change in the number of progenitor cell (CD34+ cell) from baseline to week 8. (6) The change in the number of endothelial progenitor cells (positive for DiI-acLDLuptake and FITC-lectin binding staining) from baseline to week 8. (7) The change in brachial blood pressure, estimated central aortic pressure, and heart rate from baseline to week 8. | — |
Countries
Japan
Outcome results
None listed